M.D. Anderson Cancer Center: Carcinoma, Hepatocellular trials

The registry lists 32 Carcinoma, Hepatocellular studies with M.D. Anderson Cancer Center as lead sponsor. 7 are open to participants now and 7 have results posted.

Phase 1 12Phase 2 13Phase 3 1Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image RegistrationNot yet recruitingNCT07877220Not applicable
• A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular CarcinomaRecruitingNCT07116486Phase 1
• Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis GuidelinesRecruitingNCT05143619
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
• High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver MalignanciesRecruitingNCT05053555Not applicable
• Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open HepatectomyRecruitingNCT04982653Phase 2
• Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerRecruitingNCT04380545Phase 1/2
• Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedNCT05717400Phase 4Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerCompletedNCT03222076Phase 2Results posted
• Pembrolizumab (MK-3475) in Hepatocellular CarcinomaCompletedNCT02940496Phase 2Results posted
• Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT01900002Phase 2Results posted
• Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)TerminatedNCT01821963Phase 3Results posted
• Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line TherapyCompletedNCT01180959Phase 2Results posted
• Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By SurgeryCompletedNCT00242502Phase 2Results posted
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnNCT06006286Phase 1/2
• A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast CancerActive, not recruitingNCT05394259Phase 1
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsActive, not recruitingNCT05075993Phase 1
• A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2
• Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse EventsActive, not recruitingNCT05038254Not applicable
• Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver CancerWithdrawnNCT04965714Phase 2
• Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver CirrhosisActive, not recruitingNCT04785534Not applicable
• Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid MalignanciesTerminatedNCT04785287Phase 1/2
• Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerActive, not recruitingNCT04721132Phase 2
• An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver CancerCompletedNCT04022746Not applicable
• Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)Active, not recruitingNCT03896646Not applicable
• Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver CancerActive, not recruitingNCT03028311Phase 1
• Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver FunctionTerminatedNCT02626312Phase 1
• 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or TransplantActive, not recruitingNCT02379377Phase 1
• Contrast-enhanced MRI in Detecting Benign and Malignant Liver LesionsActive, not recruitingNCT02156739Not applicable
• Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular CarcinomaCompletedNCT01176604Not applicable
• Proton Therapy and Bevacizumab for Primary Liver TumorsTerminatedNCT00426829Phase 1
• TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00077142Phase 1/2